Anti-aggregation Effect and Short-term Safety Evaluation of Low-dose Aspirin Therapy in the Elderly Chinese Population: a Multicenter Randomized Controlled Clinical Trial / 中国循环杂志
A total of 1 194 participants aged 60 or older, who should be recommended to take aspirintherapy due to medical reasons, were recruited and randomly assigned into three groups to receive enteric-coated sustained-release aspirintablet (50 mg, once daily, group A), or 100 mg, once daily (group B) or enteric-coated aspirintablet 100 mg once daily (group C), respectively. AA-Ag was measured after (14±3)days of aspirintreatment. Adverse events and bleeding events were recorded during the (28±3)days of follow-up.
Results:
The AA-Ag in group A (n=347), B (n=338) and C (n=332) post 14-day aspirintherapy were 6.65 (4.03,10.84)%, 5.89(3.22,10.03) % and 6.00(3.68,10.09) %, respectively (P>0.05). During the 28 days follow-up, the adverse events rate of group A (n=388), B (n=387) and C (n=385) was 3.87%,3.36%, and 7.95%, and the mild bleeding events rate was 3.09%, 2.33%, and 6.23%, respectively. Adverse events rate and mild bleeding events rate were significantly higher in group C than in group A and B (P<0.05).